RedHill Biopharma (RDHL) Work In Process (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Work In Process for 3 consecutive years, with $308000.0 as the latest value for Q4 2024.

  • Quarterly Work In Process rose 32.19% to $308000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $308000.0 through Dec 2024, up 32.19% year-over-year, with the annual reading at $308000.0 for FY2024, 32.19% up from the prior year.
  • Work In Process for Q4 2024 was $308000.0 at RedHill Biopharma, up from $233000.0 in the prior quarter.
  • The five-year high for Work In Process was $2.4 million in Q4 2022, with the low at $233000.0 in Q4 2023.
  • Average Work In Process over 3 years is $975333.3, with a median of $308000.0 recorded in 2024.
  • The sharpest move saw Work In Process tumbled 90.23% in 2023, then skyrocketed 32.19% in 2024.
  • Over 3 years, Work In Process stood at $2.4 million in 2022, then crashed by 90.23% to $233000.0 in 2023, then surged by 32.19% to $308000.0 in 2024.
  • According to Business Quant data, Work In Process over the past three periods came in at $308000.0, $233000.0, and $2.4 million for Q4 2024, Q4 2023, and Q4 2022 respectively.